List of Omlonti drug patents

Omlonti is owned by Santen.

Omlonti contains Omidenepag Isopropyl.

Omlonti has a total of 9 drug patents out of which 0 drug patents have expired.

Omlonti was authorised for market use on 22 September, 2022.

Omlonti is available in solution;ophthalmic dosage forms.

Omlonti can be used as method of treating open-angle glaucoma or ocular hypertension in patients.

Drug patent challenges can be filed against Omlonti from 2026-09-22.

The generics of Omlonti are possible to be released after 10 June, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648097 SANTEN Pyridylaminoacetic acid compound
Oct, 2029

(6 years from now)

US10774072 SANTEN Crystal of N-substituted sulfonamide compound
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685986 SANTEN Medical composition for treatment or prophylaxis of glaucoma
Oct, 2029

(6 years from now)

US10765750 SANTEN Pharmaceutical composition containing pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US11197849 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US9415038 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

USRE48183 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US10702511 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US10179127 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

Do you want to check out OMLONTI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: 2026-09-22

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

OMLONTI family patents

21

Japan

19

United States

7

China

7

European Union

6

Spain

5

Canada

5

Korea, Republic of

4

Australia

3

Hong Kong

3

Denmark

3

Poland

3

Portugal

3

Mexico

3

Hungary

2

Philippines

2

Malaysia

2

Turkey

2

Brazil

2

Singapore

EA

2

EA

2

New Zealand

2

Croatia

2

Cyprus

2

Israel

2

Taiwan

2

Georgia

2

Slovenia

1

Ukraine

1

San Marino

1

Chile

1

Lithuania

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in